Massachusetts health care law expected to improve access to clinical trials

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

Massachusetts Governor Charlie Baker signed into law a compromise healthcare bill that calls for reimbursing cancer patients for the out-of-pocket expenses associated with clinical trial participation and creating across the board reimbursement programs in the state.

The anticipated result is that thousands of cancer patients in Massachusetts will gain access to advanced treatments offered in clinical trials. The goal is to improve participation and retention in cancer clinical trials, especially among underserved populations.

The legislative action is the result of an effort by Lazarex Cancer Foundation and members of the state legislature, including Representative Hannah Kane, the author and lead on the cancer trial language, Leader Ronald Mariano, former Senator Richard Ross, and others, to bring attention to the issue. Co-authored by Lazarex, the legislation clarifies that reimbursing patients for the out-of-pocket expenses necessary to travel to a clinical trial site are not to be considered inducements or coercion.

Similar legislation is being considered in Florida, and New Mexico, and is already law in California, Pennsylvania, Texas, Illinois and Wisconsin.

Table of Contents

YOU MAY BE INTERESTED IN

By law, the Food and Drug Administration is required to determine whether a drug, device, biologic, or medical device is “safe and effective.” But the FDA determination does not control whether the Centers for Medicare & Medicaid Services will pay for it.  To satisfy CMS, medical products and services must be “reasonable and necessary,” meaning...

As a radiation oncologist, I am struck by how often the decisive variable in lung cancer is not the sophistication of our therapy, but the timing of our encounter with the disease.  The American Cancer Society projects 618,120 cancer deaths in the United States in 2025, with lung cancer remaining as the single largest contributor,...

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login